中化巖土(002542.SZ):“巖土轉債”的轉股價由7.99元/股向下修正至3.13元/股
格隆匯6月25日丨中化巖土(002542.SZ)公佈,鑑於此次臨時股東大會召開日前20個交易日公司股票交易均價和前一交易日均價分別為3.092元/股及3.125元/股,公司最近一期經審計的每股淨資產為2.26元,股票面值為1元,因此修正後的轉股價格應不低於3.13元/股。
綜合考慮上述價格並結合公司自身情況,公司於2021年6月25日召開第四屆董事會第五次臨時會議審議通過了《關於向下修正可轉換公司債券轉股價格的議案》,決定將“巖土轉債”的轉股價格由人民幣7.99元/股向下修正至人民幣3.13元/股,本次修正後的轉股價格自2021年6月28日起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.